Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly’s Venture Strategy Matures As PoC Data Catalysts Approach

Executive Summary

As part of a new R&D investment approach, Eli Lilly has partnered with TVM Capital and HealthCare Ventures, which have raised $250 million and funded the start of eight single-molecule companies. Corporate Business Development VP Darren Carroll discussed how the company’s venture initiative has evolved during Elsevier’s Pharmaceutical Strategic Alliance conference Sept. 25.

You may also be interested in...



Lilly's Carroll Talks Innovation, Partnering And Business Development Strategy

Eli Lilly Senior VP-Corporate Business Development Darren Carroll weighed in on pharmaceutical innovation, biotech valuations and the rising bar for external innovation during an interview at the J.P. Morgan Healthcare conference.

Better Living Through Chemistry: Biopharma Investors Weigh In

In START UP’s third annual Life Science VC Survey, those who invest in biopharmaceuticals are feeling good about the IPO window and the helping hand from corporate VCs, and for the third year in a row, they say oncology and rare diseases are top investment targets. Their skepticism about asset-based financing has grown, however, even as new twists on the model emerge.

Latest Pharma-VC Experiment: Arteaus Gets $18M For Migraine Drug Licensed From Lilly

Atlas Venture and OrbiMed Advisors have launched a virtual company to support development of a single asset, which Lilly can buy back after a Phase II trial.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS055635

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel